{"id":"W4365512785","doi":"10.1158/1538-7445.am2023-ct065","title":"Abstract CT065: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Pertuzumab; Medicine; Internal medicine; Capecitabine; Metastatic breast cancer; Oncology; Neratinib; Taxane; Trastuzumab; Progression-free survival; Breast cancer; Cancer; Colorectal cancer; Chemotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001677358,0.002017171,0.002453532,0.0006345272,0.0006220579,0.00177415,0.001539368,0.002232597,0.01344833],"category_scores_gemma":[0.001164748,0.0006816013,0.002149554,0.0006213141,0.001361119,0.001509861,0.0003919603,0.005143601,0.002834746],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001161013,"about_ca_system_score_gemma":0.002097519,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002350975,"about_ca_topic_score_gemma":0.005800367,"domain_scores_codex":[0.9995195,0.000222722,0.00003046249,0.00008380321,0.00005120931,0.00009230986],"domain_scores_gemma":[0.999325,0.00009911113,0.0001251245,0.00004619903,0.00005536931,0.0003491991],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9366376,0.01526008,0.000705359,0.0009704723,0.001321365,0.00009264865,0.00008717849,0.0006583783,0.008760208,0.0002511041,0.005807038,0.02944864],"study_design_scores_gemma":[0.9084969,0.08707383,0.001633185,0.00005513654,0.0002983776,0.00007196917,0.00002162813,0.0003537342,0.0005745201,0.0001124777,0.001291376,0.00001677907],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9424289,0.01619282,0.001669982,0.002305177,0.00125044,0.01093513,0.01137197,0.001211658,0.01263393],"genre_scores_gemma":[0.9525162,0.007751721,0.002557687,0.003301516,0.0006578531,0.007957803,0.01171524,0.0001091844,0.01343266],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01344833,"threshold_uncertainty_score":0.04498911,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1240011109960701,"score_gpt":0.4907828270774674,"score_spread":0.3667817160813973,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}